ABSTRACT
In Brazil, Leishmania braziliensis is the main causative agent of the neglected tropical disease, cutaneous leishmaniasis (CL). CL presents on a spectrum of disease severity with a high rate of treatment failure. Yet the parasite factors that contribute to disease presentation and treatment outcome are not well understood, in part because successfully isolating and culturing parasites from patient lesions remains a major technical challenge. Here we describe the development of selective whole genome amplification (SWGA) for Leishmania and show that this method enables culture-independent analysis of parasite genomes obtained directly from primary patient skin samples, allowing us to circumvent artifacts associated with adaptation to culture. We show that SWGA can be applied to multiple Leishmania species residing in different host species, suggesting that this method is broadly useful in both experimental infection models and clinical studies. SWGA carried out directly on skin biopsies collected from patients in Corte de Pedra, Bahia, Brazil, showed extensive genomic diversity. Finally, as a proof-of-concept, we demonstrated that SWGA data can be integrated with published whole genome data from cultured parasite isolates to identify variants unique to specific geographic regions in Brazil where treatment failure rates are known to be high. SWGA provides a relatively simple method to generate Leishmania genomes directly from patient samples, unlocking the potential to link parasite genetics with host clinical phenotypes.
AUTHOR SUMMARY Leishmania braziliensis is the main cause of cutaneous leishmaniasis in Brazil. Due to limitations in culturing, it is important to study the parasite in a culture-independent manner. We use selective whole genome amplification (SWGA) to explore parasite genomic diversity directly from patient biopsies. This method is inexpensive and can be broadly used to generate parasite genome sequence data sampled from different Leishmania species infecting different mammalian hosts. We found high diversity among the L. braziliensis genomes from Bahia, Brazil, which correlated with geographic location. By integrating these data with publicly available genome sequences from other studies spanning four countries in South America, we identified variants unique to Northeast Brazil that may be linked to high regional rates of treatment failure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part by grants from National Institute of Allergy and Infectious Diseases (5R01AI143790, 5T32AI007532-24, and 5R01AI149456-03). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Skin lesion biopsies were obtained with informed consent from cutaneous leishmaniasis (CL) patients seen at the Health Post of Corte de Pedra, Bahia, Brazil, in accordance with local ethical guidelines (Ethical Committee of the Federal University of Bahia Medical School, Salvador, Bahia, Brazil and the University of Pennsylvania Institutional Review Board).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to include an improved analysis of somy using SWGA, along with a new supplemental figure showing specificity of SWGA primers. Finally, the results and discussion have been modified to make it clear that the SNP analysis shown in Figure 6 is proof-of-concept
Data Availability
Raw reads for all 18 SWGA genomes are available on the Sequence Read Archive (SRA) under accession number PRJNA875085.
